Page 2 - CUA Adv Prostate Ca Drug Acccess Listing
P. 2

Drug Access Listing: Advanced Prostate Cancer

 Oral agents and Outpatient Injections







 Click on province or patient assistance programs.   The information in this document is intended for healthcare
                             professionals experienced in the treatment of prostate cancer.


                                  The drug funding descriptions found within are based on
                              information acquired from pharmaceutical manufacturers and
                                      internet resources. Please report any gaps, outdated
                                information, or inaccuracies to the CUA so that appropriate
                                                revisions can be made with future updates.

























 BC


 AB                                                         NL


 SK                                             PEI
 MB
                           QC
       ON                                            NS
                                          NB








                                                    Patient Assistance Programs



 ADT, androgen deprivation therapy; ALT, alanine transaminase; AST, aspartate transaminase; CRPC, castration-resistance prostate cancer; ECOG PS, Eastern Cooperative Oncology Group
 Performance Status; LVEF, left ventricular ejection fraction; mCRPC, metastatic castration-resistance prostate cancer; nmCRPC, non-metastatic castration-resistance prostate cancer; mCSPC, metastatic
 castration-sensitive prostate cancer; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; SRE, skeletal related event; ULN, upper limit of normal.


                                                      Page 1 | © Canadian Urological Association
                                                                                v.01-SEP-2021
   1   2   3   4   5   6   7